Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 59 Novo Nordisk's modern and new generation insulins have a stable market position in the USA USA fast-acting insulin USA premix insulin Segment volume USA long-acting insulin Segment volume LevemirⓇ share Segment volume FIASPⓇ share NovoLogⓇ share — Combined NN NovoLog® Mix 70/30 share TresibaⓇ share Combined NN tMU tMU tMU CAGR volume¹: 2.9% 80 MI penetration: 83.7% 80% 80 CAGR volume¹: (6.1%) MI penetration: 51.6% CAGR volume¹: 3.6% 100% 90 MI penetration: 72.7% 100% 70 70% 70 80 80% 60- 60% 70 80% 60 60 50 50% 50 60% 60% 50 40 40% 40 40 30 30% 30 40% 40% 30 20 20% 20 20% 20 20% 10 10% 10 10 0 0% 0 0% 0 0% Aug 2013 Aug 2018 Aug 2013 Aug 2018 Aug 2013 Aug 2018 1 CAGR for 5-year period; tMU: Thousand mega units Note: The USA trend data reflect changes to IQVIA data collection coverage and methodology as of January 2012. Modern insulin (MI) penetration is of total segment, i.e. including human insulin Source: IQVIA monthly MAT Aug, 2018 volume figures NN: Novo Nordisk changing diabetes novo nordisk

View entire presentation